肝脏疾病患者血浆中组织因子途径抑制物与抗凝血酶的表达

目的研究肝脏疾病患者血浆中组织因子途径抑制物（TFPI）与抗凝血酶（AT）的改变及其临床意义。方法TFPI抗原（TFPI：Ag）采用双夹心ELISA抗原测定法。TFPI活性（TFPI：A）采用发色底物法。AT：Ag采用免疫浊度法。AT：A采用发色底物法。结果急性中毒性肝炎14例，急性病毒性肝炎20例，慢性乙型肝炎48例，肝硬化50例，共132例肝病患者：TFPI：Ag与TFPI：A均高于正常值（P〈0．05，P〈0．01），仅失代偿期肝硬化TFPI：Ag降低（P〈0．05）。AT：Ag除失代偿期肝硬化外，均接正常值。AT：A除慢性乙肝与肝硬化低于正常值外，其他组接近正常值。结论肝病患者TFPI上调，表明组织受损与炎症存在，而AT正常或降低，表明肝细胞合成AT减少。而失代偿期肝硬化除TFPI：A保持高水平外，其余多项指标均降低，表明肝组织毁损严重，抗凝蛋白合成功能减退。

Expression of Tissue Factor Pathway Inhibitor and Antithrombin in Patients with Hepatic Disease

Objective To investigate the chang of tissue factor pathway inhibitor (TFPI) and antithrombin (AT) in the plasma of patients with hepatic disease. Methods TFPI:Ag by ELISA assay. TFPI:A by colored substrate method. AT:Ag by immune furbidimetry. AT:A by colored substrate method. Results The plasma level of TFPI : Ag (except for decompensatory phase of cirrhosis) and TFPI: A all increased than control group. The level of AT: Ag(except for decompensatory phase of cirrhosis) all consistent with normol value. AT: A except for chronic hepaitis B and hepatocirrhosis lower than normol value,other groups close to control group. Conclusion The elevation of TFPI in hepatic inflammatory disease indication of tissue injury and inflammation . The lower level of AT are expression decreased of symtheic proteins in liver. Hepatocirrhosis on the part of syntheic proteins lower preforable to other hepatic disease.